Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe (CROSBI ID 323530)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Mocroft, Amanda ; Geressu, Adam ; Beguelin, Charles ; Llibre, Josep M. ; Lazarus, Jeffrey V. ; Tomazic, Janez ; Smidt, Jelena ; Parczewski, Milosz ; Brännström, Johanna ; Sedlaček, Dalibor et al. The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe // AIDS (London), 37 (2023), 1; 91-103. doi: 10.1097/qad.0000000000003406

Podaci o odgovornosti

Mocroft, Amanda ; Geressu, Adam ; Beguelin, Charles ; Llibre, Josep M. ; Lazarus, Jeffrey V. ; Tomazic, Janez ; Smidt, Jelena ; Parczewski, Milosz ; Brännström, Johanna ; Sedlaček, Dalibor ; Degen, Olaf ; van der Valk, Marc ; Paduta, Dzmitry ; Flamholc, Leo ; Schmid, Patrick ; Orkin, Chloe ; Nielsen, Lars N. ; Hoffmann, Christian ; Beniowski, Marek ; Oprea, Cristiana ; Begovac, Josip ; Peters, Lars

engleski

The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe

BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV). METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time ; HIV/HBV, HIV/HCV, and HIV/HBV/HCV. RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5- 9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU ; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53 ; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49 ; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65 ; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups. CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups. CLINICALTRIALSGOV IDENTIFIER: NCT02699736.

Humans ; Hepatitis B virus ; Hepacivirus ; End Stage Liver Disease ; Rna

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

37 (1)

2023.

91-103

objavljeno

0269-9370

10.1097/qad.0000000000003406

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost